1. National Comprehensive Cancer Network . B-cell lymphomas (version 4.2021), https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (accessed 16 September 2021).
Google Scholar2. Sehn, LH, Salles, G. Diffuse large B-cell lymphoma. N Engl J Med 2021; 384: 842–858.
Google Scholar | Crossref | Medline3. Wang, Y, Farooq, U, Link, BK, et al. Late relapses in patients With diffuse large B-cell lymphoma treated With immunochemotherapy. JCO 2019; 37: 1819–1827.
Google Scholar | Crossref | Medline4. The era of CD19-directed therapy in diffuse large B-cell lymphoma. Lancet Oncol 2021; 22: 741–742.
Google Scholar | Crossref | Medline5. FDA . Hematology/oncology (cancer) approvals & safety notifications, www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications (accessed 18 September 2021).
Google Scholar6. Salles, G, Duell, J, Barca, EG, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020; 21: 978–988.
Google Scholar | Crossref | Medline7. Gribben, JG, Fowler, N, Morschhauser, F. Mechanisms of action of lenalidomide in B-cell Non-hodgkin lymphoma. JCO 2015; 33: 2803–2811.
Google Scholar | Crossref | Medline8. Tafasitmab . Lenalidomide. In: Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc.; 2021 [updated 9 Sept 2021; cited 21 Aug 2021]. Available from: http://online.lexi.com. Subscription required to view.
Google Scholar9. Caimi, PF, Ai, W, Alderuccio, JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 790–800.
Google Scholar | Crossref | Medline10. Zynlonta (loncastuximab tesirine) injection [package insert]. New Providence, NJ: ADC therapeutics, 2021.
Google Scholar11. Loncastuximab tesirine. In: Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc.; 2021 [updated 9 Sept 2021; cited 21 Aug 2021]. Available from: http://online.lexi.com. Subscription required to view.
Google Scholar12. Home - ClinicalTrials.gov, https://clinicaltrials.gov/ (accessed 19 September 2021).
Google Scholar13. MorphoSys, AG . A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab Plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients With newly-diagnosed diffuse large B-cell lymphoma (DLBCL). Clinical Trial Registration NCT04824092, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04824092 (25 May 2021, accessed 16 September 2021).
Google Scholar14. MorphoSys, AG . A phase 2/3, randomised, multicentre study of tafasitamab With bendamustine versus rituximab With bendamustine in patients With relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) Who Are Not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT). Clinical Trial Registration NCT02763319, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT02763319 (9 June 2021, accessed 16 September 2021).
Google Scholar15. Incyte Corporation . A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tafasitamab Plus lenalidomide in addition to rituximab versus lenalidomide in addition to rituximab in patients With relapsed/refractory (R/R) follicular lymphoma grade 1 to 3a or R/R marginal zone lymphoma. Clinical Trial Registration NCT04680052, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04680052 (10 August 2021, accessed 16 September 2021).
Google Scholar16. MorphoSys, AG . A phase II, Two-cohort, open-label, multicenter study to evaluate the safety and preliminary efficacy of MOR00208 combined With idelalisib or venetoclax in patients With relapsed or refractory CLL/SLL previously treated With bruton’s tyrosine kinase (BTK) inhibitor. Clinical Trial Registration NCT02639910, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT02639910 (20 January 2020, accessed 16 September 2021).
Google Scholar17. Bukhari, A, Chaer, FE, Koka, R, et al. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol 2019; 94: E273–E275.
Google Scholar | Crossref | Medline18. Majzner, RG, Mackall, CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med 2019; 25: 1341–1355.
Google Scholar | Crossref | Medline19. ADC Therapeutics S.A . A phase 2 randomized study of loncastuximab tesirine versus idelalisib in patients With relapsed or refractory follicular lymphoma (LOTIS 6). Clinical Trial Registration NCT04699461, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04699461 (2 August 2021, accessed 16 September 2021).
Google Scholar20. ADC Therapeutics S.A . A phase 3 randomized study of loncastuximab tesirine combined With rituximab versus immunochemotherapy in patients With relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (LOTIS-5). Clinical Trial Registration NCT04384484, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04384484 (20 August 2021, accessed 16 September 2021).
Google Scholar21. ADC Therapeutics S.A . A phase 1/2 open-label study to evaluate the safety and efficacy of loncastuximab tesirine and ibrutinib in patients With advanced diffuse large B-cell lymphoma or mantle cell lymphoma (LOTIS-3). Clinical Trial Registration NCT03684694, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT03684694 (26 April 2021, accessed 16 September 2021).
Google Scholar22. MD JPA . Phase 2, single-arm, open-label, study of loncastuximab tesirine in combination With rituximab in patients With relapsed or refractory follicular lymphoma. Clinical Trial Registration NCT04998669, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04998669 (7 August 2021, accessed 16 September 2021).
Google Scholar23. ADC Therapeutics S.A . A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination With other anti-cancer agents in patients With relapsed or refractory B-cell Non-hodgkin lymphoma (LOTIS 7). Clinical Trial Registration NCT04970901, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04970901 (10 September 2021, accessed 16 September 2021).
Google Scholar24. ADC Therapeutics S.A . A phase 1b, open-label, study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of loncastuximab tesirine in combination With R-CHOP in patients With previously untreated diffuse large B-cell lymphoma (LOTIS-8). Clinical Trial Registration NCT04974996, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04974996 (22 July 2021, accessed 16 September 2021).n
Google Scholar